Navigation Links
Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2
Date:7/29/2008

for targeting neurological and psychiatric diseases."

Dr. Ross is a leader in neurodegenerative disease research; he helped to define LRRK2 as a PD target, and is an expert in its biology. As part of the collaboration, Zenobia will have access to cell assays and animal models developed by the Ross laboratory. "We are very excited to combine our expertise in fragment-based lead discovery with the expertise of Dr. Ross," said Vicki Nienaber, Ph.D., President and Founder of Zenobia. "We are a long way from a cure, but we took the first step this week with the help of the Michael J. Fox foundation."

Zenobia's research is focused on debilitating, limited-population diseases that have no cure. Zenobia combines fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. In the future, Zenobia will focus on psychiatric diseases in parallel with increased understanding of the biology of these diseases.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit http://www.zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
2. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
3. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
4. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
5. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
6. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
7. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
8. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
11. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... has sepsis, a life-threatening condition in which bacteria or ... fast for antibiotics to help. A new device inspired ... at Harvard,s Wyss Institute for Biologically Inspired Engineering may ... "Even with the best current treatments, sepsis patients are ... of the time," said Mike Super, Ph.D., Senior Staff ...
(Date:9/15/2014)... September 15, 2014 Bioptigen ... imaging OCT system for the optical device metrology and ... EnvisuTM S4410 SDOCT for Contact Lens Metrology is ... and high complexity contact lens, IOL structures, and donor ... a complete contact lens immersed in a hydration bath ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Market by Product, by Services, by Technology, by Application - ... Whole Exome Sequencing (WES) is next-generation technology used ... the exon. The exome, which is the total of all ... genome and is actually converted into proteins after translation. It ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
Breaking Biology Technology:Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3
... , , , FORT ... Board: OMCM), a leader in integrated electronic data capture (EDC) ... selected by a leading European based Contract Research Organization (CRO) ... in rheumatoid arthritis (RA). Phase III clinical studies serve to ...
... ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc. (NYSE Amex: ... chemical threats, today reported financial and operational results for the second ... For the second quarter of 2009, PharmAthene recognized revenues ... of 2008. For the six months ended June 30, 2009 ...
... China, Aug. 13 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE ... of,modernized traditional Chinese medicine ("TCM") based in Chengdu, China, ... State Food and Drug,Administration (SFDA) to produce Sanqi Tablets ... and Yinqiao Jiedu Tablets in,dosage form of 0.5 gram/tablet ...
Cached Biology Technology:Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets 3
(Date:9/15/2014)... that reef biodiversity may not provide the level of ... In an international study published today, Professor David Bellwood ... Studies (Coral CoE) says we need to identify and ... In coral reefs, just as in any modern-day society, ... and functioning. , Professor Bellwood says, in many ...
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... Australian scientists have found that the bacterium Cupriavidus ... toxic gold compounds to their metallic form using active ... on gold surfaces but have never clearly elucidated their ... that there may be a biological reason for the ...
... . , Leishmania is a deadly parasitic disease ... million new cases reported every year. Until recently, scientists were unsure ... now been solved according to a new study published in ... a scientist at the Research Institute of the McGill University ...
... Communication Intelligence Corporation ("CIC") (OTC Bulletin Board: ... for business process automation in the financial industry* ... announced today that a top-three U.S. bank will ... rollout including several thousand recently acquired branches. , ...
Cached Biology News:Bacterium helps formation of gold 2Major discovery opens door to leishmania treatment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 2Top-Three US Bank Chooses CIC Electronic Signature Technology for Branch-Wide Deployment 3
...
CREB-2 (H-290)...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: